IMNM FY 2025 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-23.2% YoY

Gross Profit

$00.0% margin

Operating Income

-$224M-3228.8% margin

Net Income

-$212M-3060.0% margin

EPS (Diluted)

$-2.43

Cash Flow

Operating Cash Flow

-$191M

Free Cash Flow

-$201M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$683M

Total Liabilities

$49M

Stockholders' Equity

$634M

Cash & Equivalents

$653M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$9M	-23.2%
Gross Profit	$0	$9M	-100.0%
Operating Income	-$224M	-$306M	+26.7%
Net Income	-$212M	-$293M	+27.5%